Kevin

During his career Dr. Moore has been dedicated to discovery and development of promising novel molecules for treatment of serious illnesses. Dr. Moore holds a Ph.D. in Chemistry and Chemical Engineering from the California Institute of Technology (1979) and an AB in Chemistry with Certificate of Proficiency in Russian Studies from Princeton University (1974). Following a postdoctoral fellowship with Leroy Hood at Caltech, Dr. Moore served in various positions at DNAX Research Inc. (1981-2003). He was a principal in the discovery of IL-10, IL-10 receptor, and IL-23 receptor, as well as a collaborator in the discovery of the cytokine IL-23. His original research article in Science announcing the cloning of IL-10 (1990) was cited as a Pillar of Immunology: K.M. Murphy (2012) J. Immunol. 189, 2069-71. In addition his group made contributions to the molecular characterization of human Fc receptors for IgG and to the DNAX genomics-based discovery program. He was leader of or key participant in several project teams for development and transition of major early discovery projects to the parent company Schering-Plough for development. During 2004 Dr. Moore was Visiting Distinguished Research Fellow at ChemoCentryx, Inc., a company focused on developing small molecule drugs that target the chemokine system. He advised and contributed to the company’s target validation and screening programs, and was a member of the Joint Steering Committee overseeing a collaboration with a major pharmaceutical firm. In November 2004 Dr. Moore joined Avidia, Inc. as Senior Director of Target Biology where he was responsible for the company’s assay development, in vitro pharmacology and preclinical safety/toxicology programs. After Avidia’s acquisition by Amgen in October 2006 he was retained as Scientific Executive Director and later Executive Director Research, Therapeutic Discovery–Biologics at Amgen South San Francisco. Dr. Moore led and managed the integration of the Amgen Mountain View (formerly Avidia) and Amgen South San Francisco Protein Sciences groups and oversaw their contributions to numerous target discovery/validation projects, several of which advanced to safety/toxicology and clinical studies. In addition, he managed the integration of independent research monoclonal antibody groups at three different Amgen sites into one cohesive unit and aligned their work with the therapeutic antibody group. Under his leadership the research monoclonal antibody group enhanced capacity and project throughput by 15-20% while undergoing a 30% reduction in staff. Dr. Moore is coauthor of more than 50 original research publications, 18 review articles, and coinventor on 22 issued patents. Among all authors in immunology, he was ranked 10th in number of citations and 18th in citation impact, 1990-1994 as reported by Science Watch (May 1995) and The Scientist (September 1995). Dr. Moore’s experience and principal areas of expertise are target discovery/validation, assay development, recombinant proteins and monoclonal antibodies as tools for discovery/validation, and large molecule drug discovery in both small and large pharmaceutical biotechnology company settings.